Even With A 27% Surge, Cautious Investors Are Not Rewarding Agilon Health, Inc.'s (NYSE:AGL) Performance Completely
Needham Maintains Agilon Health(AGL.US) With Hold Rating
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
Express News | Needham Reiterates Hold on Agilon Healthto Hold
Agilon Health Analyst Ratings
Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
Wells Fargo Maintains Agilon Health(AGL.US) With Buy Rating, Maintains Target Price $5
Agilon Health: Strategic Focus and Conservative Guidance Drive Buy Rating Amidst Modest Q4 Improvement
Bernstein Keeps Their Hold Rating on Agilon Health (AGL)
Agilon Health To Present At TD Cowen Healthcare Conference; Webcast At 9:50 AM ET
US$3.56 - That's What Analysts Think Agilon Health, Inc. (NYSE:AGL) Is Worth After These Results
BofA Securities Maintains Agilon Health(AGL.US) With Sell Rating, Announces Target Price $2.4
Agilon Health Faces Financial Challenges Amid Rising Costs and Enrollment Risks: Analyst Recommends Sell Rating
Agilon Health's Earnings Call: Growth Amid Challenges
Benchmark Co. Maintains Agilon Health(AGL.US) With Buy Rating, Cuts Target Price to $4
Barclays Maintains Agilon Health(AGL.US) With Sell Rating, Maintains Target Price $2
Agilon Health (AGL) Receives a Sell From Barclays
Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)
Cautious Hold Rating on Agilon Health Amid Uncertainty and Cost Challenges